Marlborough-based Sepracor Inc. said it has moved a step closer to marketing its insomnia drug Lunivia in the European Union.
The European Medicines Agency issued an opinion recommending a marketing authorization for the drug, which is sold in the U.S. as Lunesta. Sepracor has an agreement with GlaxoSmithKline for worldwide commercialization of the drug.
